Alireza Hedayatfar, Nazanin Ebrahimiadib, Mohammad Zarei, Maryam Ashraf Khorasani, Mirgholamreza Mahbod, Soheila Asgari, Ahad Sedaghat
Journal: European journal of ophthalmology 2021;31(4):1961-1969
PMID: 32567354
PURPOSE
To report the clinical spectrum, viral etiologies, therapeutic interventions, timing of rhegmatogenous retinal detachments (RRD), and visual outcomes in acute retinal necrosis (ARN) syndrome in a series of polymerase chain reaction (PCR)-positive eyes.
METHODS
From January 2010 to January 2017, consecutive patients with the clinical diagnosis of ARN and a positive aqueous viral PCR were included in this observational, retrospective study.
RESULTS
Nineteen eyes found to have a clinical diagnosis of ARN, of which 18 (94.7%) had a positive viral PCR. ARN was unilateral, except in one patient. None of the fellow eyes manifested ARN during follow-up. Varicella-zoster virus (VZV) was detected in 78.0% of ARN eyes. 61.1% of eyes experienced RRD. The median time for the occurrence of RRD was 12 weeks (range: 6-25 weeks) after disease onset. No correlation was found between the etiologic viral agent (VZV vs non-VZV; = 1.000), extent of retinitis (1-2 quadrant vs 3-4 quadrants; = 0.326), administration of intravitreal ganciclovir (injected vs not injected; = 0.332), application of prophylactic laser retinopexy (applied vs not applied; = 0.326), and subsequent occurrence of RRD.At a 2-year follow-up, visual impairment (VA ⩽ 20/200) and severe visual loss (VA ⩽ light perception) were significantly higher in those complicated by RRD compared to non-RRD eyes (81.8% vs 28.6%; = 0.047, and 45.4% vs 0.0%; = 0.004, respectively).
CONCLUSION
Aqueous PCR results are highly consistent with the clinical diagnosis of ARN. Regardless of the method of management, the rate of RRD is high and is associated with a poor visual outcome.
Full Text Sources:
© Copyright 2026, Nutrition Evidence
We use cookies to improve your experience and analyze site traffic with Google Analytics. By continuing to use our site, you agree to our use of cookies. Learn more.